CytoSorbents Corporation (OTCBB: CTSO), a critical care-focused company using blood purification to treat life-threatening illnesses, announced that it has received the registered trademark for CytoSorb(R) in the European Union. CytoSorb(R) is also a registered trademark in the United States.
"This represents another important step in the branding and commercialization of CytoSorb(R) in Europe. We believe that CytoSorb(R) is a memorable name that easily invokes its use as a 'cytokine adsorber' and is compatible with the broad approval in the European Union to be used in any clinical situation where cytokines are elevated. The goal of CytoSorb(R) is to quell the massive inflammation caused by 'cytokine storm,' limit the systemic inflammatory response syndrome (SIRS), and prevent or mitigate multi-organ failure, the leading cause of death in the intensive care unit today. No other class of therapy has the potential to impact the outcome of so many life-threatening illnesses, such as sepsis, burn injury, trauma, acute respiratory distress syndrome, and pancreatitis, the way CytoSorb(R) potentially can."
About CytoSorbents and CytoSorb(R)
CytoSorbents Corporation is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption that standard blood purification cannot. In March 2011, CytoSorb(R), the Company's flagship product, achieved European regulatory approval under the CE Mark as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) for use in clinical situations where cytokines are elevated. CytoSorb(R) has demonstrated statistically significant reductions in mortality in septic patients at high risk of death and is now available for sale in Germany for the treatment of critical care illnesses under a controlled market release, with a planned broad product launch in Germany anticipated for the first half of 2012. CytoSorb(R) will be made available in other E.U. countries, assuming adequate and timely funding, and continued positive results from our clinical studies. CytoSorb(R) and other polymers under development have been designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy drugs during treatment of cancer with high dose regional chemotherapy, drug detoxification, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com.